Kristine Johnson is the executive director and chief strategist at Cognition Studio.
One of the most significant strategic challenges I see today—especially for early-stage founders—is calibrating the right balance between visionary ambition and operational credibility. Positioning a company for funding isn’t just about selling big. It’s about selling smart.
When you’re in that first conversation with an investor, they want the big picture. They want to know: What’s the big idea? What’s your value proposition? That’s where you set the stage.
But if you get to that second conversation, the focus shifts. It’s no longer just about your idea. Now, they want to know how you’re going to make it happen. It’s the “make me believe” stage. How do you actually create value through your product or service? How are you going to operationalize the vision?
The mistake I see too often is overpromising. Many founders get excited and pitch beyond what they can realistically deliver. That’s a problem. If you over-pitch and under-deliver, investor trust crumbles. The skill of securing funding is in crafting a value proposition that shows ambition but is also rooted in what you can deliver today. Let’s talk about how to approach it.
Strategic Communication Is How Vision Becomes Credible
Strategic communication isn’t just an asset; it’s a differentiator. It’s the vehicle that transforms complex ideas into credible, investible narratives. When you’re going into a pitch, it’s not just about discussing a bunch of details. You have to be able to pace the information. From my observations, founders are often so immersed in their ideas that they forget to translate them for an outside perspective. That’s a costly blind spot in high-stakes conversations. They’re so immersed in the process that they forget the people they’re pitching to aren’t.
Investors don’t need all the information at once. It’s a process. Your goal should be to present the right information at the right time. It takes time to build the story.
In your first conversation, you’re educating them on the big idea. But by the second conversation, you’re converting interest into belief. Investors want to know: How are you different? Why does this matter? And in the third conversation, they’re communicating, “Okay, show me. Say I’m invested now, what does this partnership look like?”
You’re not just pitching for money—you’re building the trust and credibility of a long-term partnership. Tesla is a great example of this. The company received criticism for its automation efforts in its Model 3 production. Elon Musk even acknowledged at one point: “Yes, excessive automation at Tesla was a mistake. To be precise, my mistake. Humans are underrated.” However, in my view, Tesla’s automation efforts showed ambition, as well as alignment between their bold vision and operational credibility. It was a preview of what Tesla would go on to do in the future.
Scientific Pitches Must Show Progress Without Overpromising
When we’re talking about new innovations, especially in health or medicine, it’s usually a much different type of conversation. Science is a slow process. It has to go through years of validation—clinical trials, FDA approvals—before you see any real impact.
So when you’re pitching a scientific or medical innovation, the reality is that the actual patient impact could be 10 years down the road. That’s a challenge because investors want to know what’s happening now. How do you navigate that?
It’s about explaining where you are today and why it matters. You have to show them the data. For medical startups, that might mean animal models or early trials. Investors need to see potential—addressable markets, unmet needs and what makes your solution different.
But you can’t guarantee outcomes this early on. That’s where you have to be careful not to overpromise.
Theranos founder Elizabeth Holmes and the single blood test scandal is a great example of what happens when you overpromise on science. Theranos became a case study in what happens when storytelling outpaces science. The lesson for today’s innovators is clear: Ambition must be anchored in evidence.
Your focus should be on what you can realistically do today while making it clear how this technology could change in the future. Investors need to see both the potential and the practical steps you’re taking to get there.
Why Patient-Centered Framing Turns Data Into Belief
When you’re pitching something that’s going to impact patients, the story becomes even more important. It’s not just about the technology—it’s about the “why.” Why does this innovation exist? Is it replacing something? Is it disrupting the market? You need to explain why this matters in a way that connects with both the science and the human impact.
For example, with radioisotopes used to treat cancer, most people would reasonably think, “Why would you put radioactive material in the body? Isn’t that dangerous?” But in the context of targeted cancer treatment, it’s exactly what you want—because it goes right where it needs to. That’s an example of the story investors need to understand. You’re not just talking about science, you’re explaining why this matters for the patients who will benefit from it.
But again, you can’t overpromise. Just because a drug or technology works in early models doesn’t mean you can guarantee patient outcomes. What you need to do is focus on showing the data and demonstrating the potential. Explain the steps you’re taking today and how they’ll lead to that patient impact in the future.
The whole process of securing funding is about telling the right story at the right time. You need to understand the value you’re creating and communicate that clearly. Whether you’re articulating a scientific breakthrough or positioning a commercial roadmap, the funding conversation is ultimately a test of strategic clarity. If you can match your message to the moment—balancing potential with proof—you’re not just pitching. You’re building the foundation for a partnership rooted in belief, trust and shared ambition.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
